Bolt Biotherapeutics Ownership
| BOLT Stock | USD 0.63 0.01 1.56% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Bolt |
Bolt Stock Ownership Analysis
About 60.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.28. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bolt Biotherapeutics recorded a loss per share of 1.74. The entity last dividend was issued on the August 29, 2014. The firm had 3:2 split on the January 31, 2008. Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California. Bolt Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 91 people. For more info on Bolt Biotherapeutics please contact Randall Schatzman at 650 665 9295 or go to https://www.boltbio.com.Besides selling stocks to institutional investors, Bolt Biotherapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Bolt Biotherapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Bolt Biotherapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Bolt Biotherapeutics Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Bolt Biotherapeutics are currently held by insiders. Unlike Bolt Biotherapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Bolt Biotherapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Bolt Biotherapeutics' insider trades
Bolt Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bolt Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bolt Biotherapeutics backward and forwards among themselves. Bolt Biotherapeutics' institutional investor refers to the entity that pools money to purchase Bolt Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-06-30 | 370.8 K | Renaissance Technologies Corp | 2024-06-30 | 276.7 K | Blackrock Inc | 2024-06-30 | 267.1 K | Adar1 Capital Management Llc | 2024-06-30 | 186 K | Marquette Asset Management Inc. | 2024-06-30 | 113.8 K | Fmr Inc | 2024-06-30 | 86.6 K | Bridgeway Capital Management, Llc | 2024-06-30 | 85.2 K | Prudential Financial Inc | 2024-06-30 | 54.4 K | Two Sigma Securities, Llc | 2024-06-30 | 53.9 K | Tang Capital Management Llc | 2024-06-30 | 3.8 M | Vivo Capital, Llc | 2024-06-30 | 3.5 M |
Bolt Biotherapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bolt Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bolt Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bolt Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bolt Biotherapeutics Outstanding Bonds
Bolt Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bolt Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bolt bonds can be classified according to their maturity, which is the date when Bolt Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US09778PAC95 Corp BondUS09778PAC95 | View | |
| US09778PAA30 Corp BondUS09778PAA30 | View | |
| US09778PAB13 Corp BondUS09778PAB13 | View | |
| US097793AE35 Corp BondUS097793AE35 | View | |
| US097751BX80 Corp BondUS097751BX80 | View | |
| BBDBCN 75 01 FEB 29 Corp BondUS097751BZ39 | View | |
| BOMBARDIER INC 7875 Corp BondUS097751BT78 | View | |
| US097751BV25 Corp BondUS097751BV25 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.